Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
FORE Biotherapeutics secures $67.4 million in Series D-2 extension financing, co-led by SR One and Medicxi, to advance plixorafenib development.
PRIVATEJul 07, 2026•19 days ago
Amount Raised
$67.4 Million
Round Type
Series D
PhiladelphiaBiotechnologyHealth CareTherapeutics
Investors
3 B CapitalSamsungWindham Life Science PartnersNovartis Venture FundCormorant CapitalWellington ManagementHbm Healthcare InvestmentsOrbi Med AdvisorsAxilPrimer VenturesLg Technology VenturesTai AxSym BiosisMedicxiSr One
Description
FORE Biotherapeutics announced the closing of an upsized Series D-2 extension financing of $67.4 million, totaling $110 million raised for the Series D-2. The financing will support the late-stage development of plixorafenib. Proceeds will help deliver data from the FORTE study's tumor basket and aid in further drug development.
Company Information
Company
Fore Biotherapeutics
Location
3675 MARKET STREET
Philadelphia, Pennsylvania, United States
About
Fore Bio is a precision oncology company dedicated to developing innovative treatments that provide better outcomes for patients with the hardest-to-treat cancers. The Company’s lead asset plixorafenib (FORE8394; formerly PLX8394) is a V600 and non-V600 BRAF inhibitor with manageable clinical safety and early efficacy signals in an ongoing Phase 1/2a clinical trial. The Fore Bio research and development team is optimizing drug development by identifying existing compounds with known clinical profiles and a clear path through clinical development to advance new medicines for patients without treatment options.
PhiladelphiaBiotechnologyHealth CareTherapeutics